fenofibrate has been researched along with hydroxypropylmethylcellulose acetate succinate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, RR; Ilasi, N; Sekulic, SS; Zelesky, T | 1 |
| Birk, G; Dressman, JB; Herbert, E; Lubda, D; Saal, C; Wieber, A | 1 |
| Dressman, JB; Griffin, BT; Herbert, E; Lubda, D; Nagarsekar, K; O'Driscoll, CM; O'Shea, JP; Saal, C; Wieber, A; Witt, V | 1 |
3 other study(ies) available for fenofibrate and hydroxypropylmethylcellulose acetate succinate
| Article | Year |
|---|---|
Simultaneously measuring concentrations of a model drug and a model excipient in solution using ultrasonic spectrometry.
Topics: Drug Compounding; Excipients; Fenofibrate; Kinetics; Linear Models; Methylcellulose; Pharmaceutical Preparations; Quality Control; Solutions; Spectrum Analysis; Temperature; Ultrasonics; Water | 2005 |
Mesoporous silica-based dosage forms improve release characteristics of poorly soluble drugs: case example fenofibrate.
Topics: Delayed-Action Preparations; Drug Compounding; Fasting; Fenofibrate; Gastric Juice; Hypolipidemic Agents; Hypromellose Derivatives; Intestinal Secretions; Kinetics; Methylcellulose; Models, Chemical; Nanoparticles; Particle Size; Porosity; Povidone; Pyrrolidines; Silicon Dioxide; Solubility; Technology, Pharmaceutical; Vinyl Compounds | 2016 |
Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate.
Topics: Administration, Oral; Animals; Biological Availability; Dosage Forms; Fenofibrate; Hypolipidemic Agents; Male; Methylcellulose; Porosity; Silicon Dioxide; Solubility; Swine | 2017 |